Results 51 to 60 of about 21,874 (160)
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson +5 more
wiley +1 more source
Objective This study aimed to evaluate the efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer using a network meta-analysis approach.
Chaoyang Wang, Dong Xiao, Chao Zhai
doaj +1 more source
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita +3 more
wiley +1 more source
Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib
Objective To explore the role of interleukin-6 (IL-6) in lapatinib-resistant HER2-positive breast cancer cells BT-474. Methods Lapatinib-resistant BT-474 (BT-474R) cells were established. Western blot was used to test P-gp expression.
HU Xiaohong +4 more
doaj +1 more source
The role of extracellular vesicles in cell–cell crosstalk in cardiotoxicity
Abstract figure legend Administration of a pharmacological agent can result in off‐target cardiotoxicity which can be driven by cell–cell crosstalk between healthy and dysfunctional cardiac cells. Extracellular vesicles (EVs) are lipid bilayer structures that can move biological cargo between cells, facilitating cell–cell crosstalk.
Gabriella Bachynskyj‐Bilas +5 more
wiley +1 more source
Lapatinib Induced Suicidal Death of Human Erythrocytes
Background/Aims: The human epidermal growth factor receptors tyrosine kinase inhibitor lapatinib has been shown to trigger suicidal death or apoptosis of tumor cells and is thus used for the treatment of malignancy.
Jens Zierle +3 more
doaj +1 more source
A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer
ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy +10 more
wiley +1 more source
ABSTRACT Background It has previously been demonstrated that the nuclear factor of activated T cells (NFAT) is crucial for the development of tumors. Given OSCC's drug resistance and poor outcomes, identifying NFAT‐associated prognostic genes is urgent for better treatment.
Julaiti Tuerxun +2 more
wiley +1 more source
Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng +9 more
wiley +1 more source
Machine Learning Enables Rapid Prediction of Acid‐Reducing Agent Drug Interactions: A Streamlined Complement to PBPK Modeling. ABSTRACT pH‐dependent drug–drug interactions (DDIs) commonly occur when acid‐reducing agents (ARAs) are co‐administered with weakly basic drugs.
Yuanfang Qin +6 more
wiley +1 more source

